Cerebrospinal fluid β-amyloid((1-42)) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease

Archives of Neurology

Volumn 56, Issue 6, 1999, Pages 673-680

  Andreasen, Niels ^a   Hesse, Camilla ^b   Davidsson, Pia ^b   Minthon, Lennart ^c   Wallin, Anders ^b   Winblad, Bengt ^d   Vanderstichele, Hugo ^e   Vanmechelen, Eugeen ^e   Blennow, Kaj ^b  

^a Pitea River Valley Hospital   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e INNOGENETICS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE;

EID: 0033061647     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.6.673     Document Type: Article

References (62)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
2. Glenner GG, Wong CW. Alzheimer's disease: initial report of purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885-890.
3. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245-4249.
4. Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325:733-736.
5. Haass C, Schlossmacher MG, Hung AY, et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature. 1992;359:322-325.
6. Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature. 1992;359:325-327.
7. Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science. 1992;258:126-129.
8. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38:643-648.
9. Southwick PC, Yamagata SK, Echols CL, et al. Assessment of amyloid β protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J Neurochem. 1996;66:259-265.
10. Nitsch RM, Rebeck GW, Deng M, et al. Cerebrospinal fluid levels of amyloid β-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol. 1995;37:512-518.
11. Pirttilä T, Mehta PD, Lehtimäki T, et al. Relationship between apolipoprotein E4 allele and CSF amyloid β-protein in Alzheimer's disease and controls. Neurosci Res Commun. 1994;15:201-207.
12. Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y. High tissue content of soluble β1-40 is linked to cerebral amyloid angiopathy. Am J Pathol. 1994; 145:452-460.
13. Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L, Gambetti P. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun. 1994;200:1598-1603.
14. Nakamura T, Shoji M, Harigaya Y, et al. Amyloid β protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann Neurol. 1994;36: 903-911.
15. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monocloncals: evidence that an initially deposited species is Aβ42(43). Neuron. 1994;13:45-53.
16. Tamaoka A, Kondo T, Odaka A, et al. Biochemical evidence for the long-tail form (Aβ 1-42/43) of amyloid β protein as a seed molecule cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun. 1994;205:834-842.
17. Miller DL, Papayannopoulos IA, Styles J, et al. Peptide composition of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys. 1993;301:41-52.
18. Gravina SA, Ho L, Eckman CB, et al. Amyloid beta protein (A beta) in Alzheimer's disease brain: biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem. 1995;270: 7013-7016.
19. Prelli F, Castano E, Glenner GG, Frangione B. Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem. 1988;51:648-651.
20. Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk D. Characterization of β-amyloid peptide from human cerebrospinal fluid. J Neurochem. 1993;61: 1965-1968.
21. Tamaoka A, Sawamura N, Fukushima T, et al. Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci. 1997;148:41-45.
22. (1-42) in CSF. In: Fisher A, Hanin I, Yoshida, M, eds. Progress in Alzheimer's and Parkinson's Diseases. New York, NY: Plenum Publishing Corp; 1998:773-778.
23. Ida N, Hartmann T, Pantel J, et al. Analysis of heterogeneous βA4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem. 1996;271:22908-22914.
24. Andreasen N, Sjōdin C, Blennow K, Winblad B, Svärsudd K. Prevalence and incidence of memory recall disturbances in a geographically defined general population: the Piteå Dementia Project. Neuroepidemiology, in press.
25. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med. 1996;47:387-400.
26. Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett. 1992;135: 235-238.
27. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci U S A. 1993;90: 1977-1981.
28. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to β-amyloid. J Biol Chem. 1994;269: 23403-23406.
29. Richey PL, Siedlak SL, Smith MA, Perry G. Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis. Biochem Biophys Res Commun. 1995;208:657-663.
30. Blennow K, Wallin A, Uhlemann C, Gottfries CG. White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand. 1991;83:187-193.
31. Scheltens P, Weinstein HC, Leys D. Neuro-imaging in the diagnosis of Alzheimer's disease, I: computer tomography and magnetic resonance imaging. Clin Neurol Neurosurg. 1992;94:277-289.
32. Folstein M, Folstein S, McHugh P. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
33. Vanmechelen E, Blennow K, Davidsson P, Cras P, Van de Voorde A. Combination of tau/phospho-tau with other biochemical markers for Alzheimer CSF diagnosis and tau in CSF as marker for neurodegeneration. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM, eds. Alzheimer's Disease: Biology, Diagnosis and Therapeutics. New York, NY: John Wiley & Sons Inc; 1997: 197-203.
34. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med. 1997;3:67-72.
35. 42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94:1550-1555.
36. Kane JW, Gowland G. A method for the identification of apolipoprotein E isoforms employing chemical precipitation and flat bed isoelectric focusing in agarose. Ann Clin Biochem. 1986;23:509-513.
37. International Federation of Clinical Chemistry (IFCC). Approved recommendation on the theory of reference values: part 5: statistical treatment of collected reference values: determination of reference limits. Clin Chim Acta. 1987;170(pt 5):13-32.
38. Kuo YM, Emmerling MR, Vigo-Pelfrey C, et al. Water soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1990;271: 4077-4081.
39. Roher AE, Palmer KC, Yurewicz EC, Ball MJ, Greenberg BD. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J Neurochem. 1993;61:1916-1926.
40. Jarret JT, Berger EP, Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci. 1993;695:144-148.
41. Fishman RA. Cerebrospinal Fluid in Diseases of the Nervous System. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1992.
42. Davies L, Wolska B, Hilbich C, et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease. Neurology. 1988;38:1688-1693.
43. Permanne B, Buée L, David JP, Fallet-Bianco C, Di Menza C, Delacourte A. Quantitation of Alzheimer's amyloid peptide and identification of related amyloid proteins by dot-blot immunoassay. Brain Res. 1995;685:154-162.
44. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541:163-166.
45. Tomlinson BE, Henderson G. Some quantitative cerebral findings in normal and demented old people. In: Terry RD, Gershon S, eds. Neurobiology of Aging. New York, NY: Raven Press; 1976:183-204.
46. Mountjoy CQ, Roth M, Evans NJR, Evans HM. Cortical neuronal counts in normal elderly controls and demented patients. Neurobiol Aging. 1983;4:1-11.
47. Hubbard BM, Anderson JM. Age-related variations in the neuron content of the cerebral cortex in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol. 1985;11:369-382.
48. Mann DMA. The neuropathology of Alzheimer's disease: a review with pathoge netic, aetiological and therapeutic considerations. Mech Ageing Dev. 1985;31: 215-255.
49. Davidsson P, Blennow K. Neurochemical dissection of synaptic pathology in Alzheimer's Disease. Int Psychogeriatrics 1998;10:11-23.
50. Roth M. The association of clinical and neurological findings and its bearing on the classification and aetiology of Alzheimer's disease. Br Med Bull. 1986;42:42-50.
51. Rothschild D. Pathologic changes in senile psychoses and their psychobiologic significance. Am J Psychiatry. 1937;97:757-788.
52. Sourander P, Sjögren H. The concept of Alzheimer's disease and its clinical implications. In: Wholstenholme GEW, O'Connors M, eds. Alzheimer's Disease. Ciba Foundation Symposium. London: Churchill; 1970:11-36.
53. Constantinidis J. Is Alzheimer's disease a major form of senile dementia? clinical, anatomical and genetic data. In: Katzman R, Terry RD, Bick KL, eds. Alzheimer's Disease: Senile Dementia and Related Disorders. Aging Vol. 7. New York, NY: Raven Press; 1978:15-25.
54. Mann DMA, Yates PO, Marcyniuk B. Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol. 1984;10: 185-207.
55. Hansen LA, DeTeresa R, Davies P, Terry RD. Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer's disease. Neurology. 1988;38:48-54.
56. George AE, de Leon M, Gentes C, et al. Leukoencephalopathy in normal and pathologic aging, I: CT of brain lucencies. Am J Neuroradiol. 1986;7:561-566.
57. Erkinjuntti T, Ketonen L, Sulkava R, Vuorialho M, Palo J. CT in the differential diagnosis between Alzheimer's disease and vascular dementia. Acta Neurol Scand. 1987;75:262-270.
58. Wallin A, Blennow K, Uhlemann C, Långström G, Gottfries CG. White matter low attenuation on computed tomography in Alzheimer's disease and vascular dementia: diagnostic and pathogenic aspects. Acta Neurol Scand. 1989;80: 518-523.
59. Tomlinson BE. Morphological changes and dementia in old age. In: Lynn Smith W, ed. Aging and Dementia. New York, NY: Spectrum Publications; 1977: 25-56.
60. Blennow K, Wallin A. Clinical heterogeneity of probable Alzheimer's disease. J Geriatr Psychiatry Neurol. 1992;5:106-113.
61. Scheltens P, Barkhof F, Valk J, et al. White matter lesions on magnetic resonance imaging in Alzheimer's disease: evidence for heterogeneity. Brain. 1992; 115:735-748.
62. Blennow K, Wallin A, Häger O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol Scand. 1993;88:221-223.